The Rights Issue is being carried out to strengthen the company’s financial position, provide additional scope for the ongoing commercialization of Pepaxti in Europe, and advance the company’s preclinical project for the indication glioblastoma to the clinical development phase, which includes conducting an initial so-called ’window-of-opportunity’ study in human.

The company’s largest shareholder, HealthCap VIII LP, has undertaken to subscribe for shares in the Rights Issue for SEK 20 million, and certain members of the company’s board of directors and senior management intend to enter into binding subscription commitments following the publication of the company’s interim report for the fourth quarter of 2025. The company has also entered into guarantee commitments totaling SEK 170 million. The company has thus obtained subscription commitments, subscription intentions and guarantee commitments covering the Rights Issue up to SEK 190 million.

“In 2025, Oncopeptides has doubled its net sales and established Pepaxti as an important treatment option in Germany, Austria, Spain and Italy. Through the rights issue we are presenting today, we are strengthening our financial resilience to bridge our commercial operations toward positive cash flow in 2027,” says Sofia Heigis, CEO of Oncopeptides. “The proceeds enable us to maintain momentum in our European launch while simultaneously accelerating the development of our PDC platform toward indications beyond multiple myeloma. We particularly look forward to initiating our clinical study in glioblastoma in 2026, where we have the potential to address a significant unmet medical need. In parallel with our ongoing discussions with a potential partner in Japan, which are now focused on reaching an agreement, together with a strategic review of our German organization and our R&D operations, the issue provides the company with a solid foundation to create value for both shareholders and patients.”